Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells.
Neuroendocrine cells have traits similar to those of nerve cells and hormone-producing cells.
Neuroendocrine tumors are rare and can occur anywhere in the body.
The term neuroendocrine tumor generally refers to a well differentiated disease, while neuroendocrine carcinoma refers to poorly differentiated disease: Neuroendocrine neoplasms is an umbrella term for both.
NETs are thought to arise from cells throughout the diffuse endocrine system.
Most neuroendocrine tumors occur in the lungs, appendix, small intestine, rectum and pancreas.
Estimated incidence is 6.98 cases per hundred thousand people and is increasing with the prevalence estimated at greater than 170,000 in the US.
Misdiagnosis was common (44%) in these patients, and mean time to diagnosis was around 5 years.
Because NETs can present in different areas of the body, lead to diverse symptoms, and are rare, timely diagnosis and management are challenging.
Rates are increasing rapidly, potentially due to improved awareness of the condition and diagnostic tools.
There are many types of neuroendocrine tumors.
Some grow slowly and some grow very quickly.
Some neuroendocrine tumors produce excess hormones and are functional neuroendocrine tumors.
Up to 25% of NETs are functional and releasendistinctive hormones into the bloodstream, including amines, polypeptides, and prostaglandins.
Others tumors don’t release hormones or do not release enough to cause symptoms and are nonfunctional neuroendocrine tumors,
Neuroendocrine tumors are highly vascular tumors and vascular endothelial growth factor is a key driver of angiogenesis.
Neuroendocrine tumors are classified, according to the site of origin, morphologic features, grade, and differentiation.
NET’s are subclassified as well differentiated or poorly differentiated.
The grade is based on the KI-67 proliferative index and/or mitotic rate.
The grade may be low with the KI-67 in less than 3%, moderate with a KI-67 of 3 to 20%, or high with KI-67 greater than 20%, related to grades 1,2, and 3 respectively.
The term neuroendocrine tumor refers to a well differentiated neoplasm, whereas neuroendocrine carcinoma, indicates a poorly differentiated carcinoma.
Neuroendocrine tumor grade 3 covers all highgrade neuroendocrine malignanciess with a KI 67 higher than 20%: Grade 3 NET is well differentiated and neuroendocrine carcinoma if it is poorly differentiated.
G3 NET makes up approximately 18% of all Neuroendocrine neoplasms.
The most common primary organ of an NET G3 is the pancreas (65%).
Pancreatic NETs are associated with a relatively high expression of VEGF receptor 2, 3, platelet derived growth factor receptor.
Diagnosis and treatment of neuroendocrine tumors depend on the type of tumor, its location, whether it produces excess hormones, how aggressive it is and whether it has spread to other parts of the body.
Types of NETs
Merkel cell carcinoma
Pancreatic neuroendocrine tumors
NET‘s may arise in the context of inherited genetic syndromes, including multiple endocrine neoplasia types one, two, and four and with succinate dehydrogenase mutations.
NET‘s have been associated with Von Hippel-Lindau disease, tuberous sclerosis complex, neurofibromatosis, MEN1, and MEN2,
Neuroendocrine tumors don’t always cause signs and symptoms at first.
Symptoms experienced depend on the location of the tumor and whether it produces excess hormones.
Patients have functional tumors when associated with hormonal symptoms, and for those without symptoms they have non-functional tumors.
Symptoms include intermittent flushing and diarrhea in patients with gastrointestinal NET‘s, bronchospasm and wheezing in lung NETs, hypertension in patients with pheochromocytoma or paragangliomas, and symptoms attributable to secretion of insulin, glucagon, gastrin, and other peptides in patients with pancreatic NETs.
In general, neuroendocrine tumor signs and symptoms might include:
Pain from an expanding tumor.
A growing mass you can palpate.
Losing weight without trying
Neuroendocrine tumors that produce excess hormones
Functional neuroendcrine tumors might cause:
Diarrhea with NET‘s can be multifactorial: exocrine pancreatic insufficiency, short bowel syndrome, bacterial overgrowth, and bile acid malabsorption.
Exocrine pancreatic insufficiency develops in the majority of patients on somatostatin analogues.
NETs staining with synaptophysin and chromogranin and have epithelial markers of cytokeratin and CAM.
hormonally inactive peptides, such as chromogranin A and pancreatic polypeptide conserve his tumor markers for non-functioning NETs.
Evaluation of serotonin secretion using 24 hour urine or plasma 5-HIAA is indicated for carcinoid syndrome.
NETs are grouped in three grades based on the KI-67 proliferative index and mitotic rate, which have prognostic and treatment applications.
NETs are characterized as well differentiated tumors, and poorly differentiated tumors are classified as Neuroendocrine carcinomas.
Tumorigenesis and molecular pathogenesis a highly variable depend on the tumor location.
Mutations of chromatin remodeling MEN 1, DAXX, and ATRX are common in pancreatic NETs and correlate with poor prognosis.
Small bowel NETs have mTOR pathway alterations in approximately 1/3 of tumors and gain of function in chromosomes 4, 5, and 14 with loss of chromosome 18 and in activation of CDKN 1/APC.
In small bowel NETs pathway alterations occur in approximately 1/3 of tumors.
Small bowel NET‘s are mostly sporadic.
NET‘s are classified as functional or non-functional.
25% of all NETs are functional.
Treatment is focused on controlling both tumor growth and symptoms of functional tumors.
Curative resection is generally recommended whenever possible.
Bronchial/pulmonary NETs: surgical resection with curative intent is the preferred approach for stages I through III when possible.
All poorly differentiated neuroendocrine carcinomas are grade 3.
Imaging is most effective with somatostatin receptor scintography with PET/CT scans using gallium68 and Cu 64.
GA-DOTATE positron emission tomography/CT has become the preferred imaging owing to its superior ability in detection of gastrointestinal pancreatic- NETs when compared with standard anatomic and octeotide imaging.
These have a different prognosis and different clinical approach to treatment.
Treatment decisions depend upon the disease biology, symptom burden, disease extent, patient comorbidities, and patient preference.
Surgery is considered with curative intent at an early stage or in localized NETs.
If possible, localized low and intermediate grade ET‘s should be respected with negative margins and lymph node dissection should be considered in most cases.
Median time for recurrence is 8.7 years in small intestine NETs and 7.2 years for pancreatic NETs: suggesting surveillance particularly with MRI for younger patients to reduce radiation exposure.
Lver directed therapies including surgical resection, hepatic arterial embolization, percutaneous thermal ablation may be considered for patients who have progressed on systemic therapy and have symptomatic disease.
Observation for early nonfunctioning pancreatic, neuroendocrine tumors of 2 cm or less is supported by current guidelines.
Neuroendocrine tumors are one malignancy where surgery for advanced or metastatic disease is a consideration, when greater than 70-90% of the disease can be resected, or when tumor debunking of functional tumors is needed in symptomatic patients.
Not all patients with advanced disease require therapy and the disease can be observed with tumor markers and imaging studies to establish the burden of disease and its progression.
Functional NET tumors cause distinct syndromes such as carcinoid syndrome because of secreted peptides and neuroamines.
Patients with syndrome symptoms of hormone secretion often benefit from treatment with somatostatin analogues including octreotide, lanreotide, pasireotide and telotristat.
Peptide receptor radionuclide therapy exploits the expression of somatostatin receptors on the surface of NET cells and delivers a radionuclide at the cellular level.
Radio active labeled agents are composed of radionucleotide isotopes such as yttrium 90, or lutetium 77.
Overall regardless of the site of origin curative resection is recommended.
Adjuvant therapy has no role in the management of well differentiated NETs.
For bronchial/pulmonary NETs surgical resection with curative intent is preferred for stage is I-III, when possible.
Local regional bronchial and thymic NETs have a five-year survival rate after curative resection is high as 97%.
The survival of patients with atypical carcinoids and a higher T stage is inferior to patients with typical carcinoids and smaller primary tumors.
Targeted therapy with everolimus, radionuclide therapy, interferon, cytotoxic chemotherapy, and liver directed therapy for hepatic predominant disease.
Lu-177-Dotatate A peptide receptor radioclide therapy is available.
In patients with SSTR positive GEP-NETs LU-Dotatate has been shown to offer disease control and survival benefit.
Lu-177-Dotatate Dosing is every eight weeks for four treatments.
Gastroduodenal NETs categorized into three types.
Type one gastric NETs are associated with gastric achlorhydria and are the most benign type, constituting 70 to 80% of all gastric NETs.
Type 2=gastric NETs occur as part of multiple endocrine neoplasia 1 syndrome it is associated with pancreatic duodenal gasttinomas.
Type 3 gastric NETs are sporadic and occur in the absence of gastric achlorhydria or Zollinger-Ellison syndrome and may constitute up to 20% of all gastric NETs.
Most patients with gastric NETs have local or hepatic metastases at the time of presentation.
Surgical resection depends on the type and functional status of the tumor.
Active surveillance is reasonable in subcentometer gastric NETs.
Surgical resection of pancreatic NETs is the mainstay of therapy except for high-grade tumors, symptomatic or functional tumors, and tumors measuring at least 2 cm.
For patients with larger tumors in whom lymph node metastasis is strongly suspected a Whipple procedure is the preferred approach.
Surgical resection of primary disease and disease debulking along with systemic therapy may play a role in the management of symptomatic and functional pancreatic NETs.
Surgical resection is the cornerstone of treatment for midgut NETs involving the small and large bowel.
With appendiceal NETs appendectomy is preferred when the tumor is smaller than 1 cm and the right hemicolectomy is considered when tumor is a larger than 2 cm.
The liver is the most common site distant NET metastases, and hepatic metastases are a major predictor of survival in this disease.
Liver directed therapy is an option for patients with predominantly liver metastasis.
Systemic agents such as tyrosine kinase inhibitors and chemotherapy for pancreatic NETs and m-TOR inhibitors are considered.
Sunitinib, a multi targeted tyrosine kinase inhibitor can be used for advanced pancreatic neuroendocrine tumors with the response rate of 9%.
Everolimus is approved for neuroendocrine tumors with studies, showing a median progressive free survival of 11.0 versus 4.6 months in placebo studies.
80 to 90% of small bowel NETs and 60 to 70% of pancreatic NETs eventually metastasize to the liver.
Surgical resection of a primary tumor along with neuroendocrine liver metastases, when feasible, has been associated with prolonged progression free survival.
Segmental resection, radiofrequency ablation, and transarterial procedures with chemoembolization and transarterisl radio embolization are other alternatives that can provide durable disease control of liver disease.
In patients with liver metastasis liver transplant may be an option with a five year overall survival rate of 63%.
Somatostatin analogues, are typically the first line therapy to control the growth of a well differentiated NET.
Octreotide is approved for hormonal control of NETs, while lanreotide is approved for tumor control as well.
Luteum177 is a therapeutic consideration for somatostatin receptor positive gastroenteropancreatic NETs.
In the NETTER –1 trial Lutetium LU 177 in patients with advanced, somatostatin receptor positive midgut NETs that had progressed on standard octreotide therapy had a overall response rate of 18% with a 79% reduction in risk for death.
Chemotherapy with efficacy include: streptozotocin, temozolomide, 5FU, capecitabine and oxaliplatin.
Neuroendocrine tumor associated hormonal syndromes include insulinoma, gastrinoma (Zollinger Ellison syndrome, VIPoma, somatostatinoma and glucagonoma.
Management of NETs depend on factors related to the symptoms, pace of disease progression, and disease location.
Surveillance may be used in patients with low grade tumors and low tumor burden, who are asymptomatic, who have non-functional, stable, low-grade midgut tumors with a KI 67 index no higher than 10%.